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BACKGROUND Diabetes mellitus causes microcirculatory rarefaction and may impair the 
responsiveness of ischemic myocardium to proangiogenic factors.  
OBJECTIVES We sought to determine whether microvascular destabilization affects organ 
function and therapeutic neovascularization in diabetes mellitus. 
METHODS We obtained myocardial samples from patients with end-stage heart failure at time 
of transplant, with or without diabetes mellitus. Diabetic (db) and wild-type (wt) pigs were used 
to analyze myocardial vascularization and function. Chronic ischemia was induced 
percutaneously (day 0) in the circumflex artery. At day 28, recombinant adeno-associated virus 
(rAAV, 5 x 1012 viral particles encoding vascular endothelial growth factor-A [VEGF-A] or 
Thymosin β4 [Tβ4]) was applied regionally. CD31+ capillaries per high power field (c/hpf) and 
NG2+ pericyte coverage (p/hpf) were analyzed. Global myocardial function (ejection fraction 
[EF] and left ventricular end-diastolic pressure) was assessed at days 28 and 56.  
RESULTS Diabetic human myocardial explants revealed capillary rarefaction and pericyte loss 
compared to nondiabetic explants. Hyperglycemia in db pigs, even without ischemia, induced 
capillary rarefaction in the myocardium (163 ± 14 c/hpf in db vs. 234 ± 8 c/hpf in wt hearts; p < 
0.005), concomitant with a distinct loss of EF (44.9% vs. 53.4% in nondiabetic controls; p < 
0.05). Capillary density further decreased in chronic ischemic hearts as did EF (both p < 0.05). 
Treatment with rAAV.Tβ4 enhanced capillary density and maturation in db hearts less efficiently 
than in wt hearts, similar to collateral growth. rAAV.VEGF-A, though stimulating angiogenesis, 
did not induce pericyte recruitment nor collateral growth. As a result, rAAV.Tβ4 but not 
rAAV.VEGF-A improved EF in db hearts (34.5 ± 1.4%), but less so than in wt hearts (44.8 ± 
1.5%). 
CONCLUSIONS Diabetes mellitus destabilized microvascular vessels of the heart, affecting the 
amplitude of therapeutic neovascularization via rAAV.Tβ4 in a translational large animal model 
of hibernating myocardium. 
 
KEY WORDS angiogenesis, chronic myocardial ischemia, gene therapy, Thymosin ß4 
 
ABBREVIATIONS AND ACRONYMS  
Ang = angiopoietin 
db = diabetic 
hpf = high power field 
LVEDP = left ventricular end-diastolic pressure 
miR = micro ribonucleic acid 
rAAV = recombinant adeno-associated virus 
RCx = ramus circumflexus 
Tβ4 = thymosin beta 4 
VEGF-A = vascular endothelial growth factor A 
wt = wild type 
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Diabetes mellitus (DM) is one of the most important risk factors for developing cardiovascular 
disease (1,2). Moreover, DM induces additional major adverse coronary events after 
percutaneous coronary interventions (3-6) and bypass grafting, particularly if poorly controlled 
(7). This comparative disadvantage is also evident when interventions are performed for acute 
coronary syndromes (8) and for chronic coronary lesions, aimed at resolving contractile 
dysfunction in viable myocardium (i.e., hibernating myocardium) (9,10). 
Apparently, macrovascular treatment options for coronary obstructions are antagonized 
by additional factors beyond the reach of conventional recanalization strategies (11). A 
continuous inflammatory disposition of microvessels has been attributed to vessel regression in 
most organs (12), except for reactive inflammatory vessel growth in the eye (13). Both 
rarefaction and capillary sprouting imply vessel destabilization as a common denominator. In 
this concept, pericyte detachment is caused by inflammatory endothelial activation (13). The 
diabetic inflammatory process might be aggravated by exogenous vessel-destabilizing factors 
such as vascular endothelial growth factor (VEGF)-A (14), potentially blunting its efficacy in 
therapeutic neovascularization. Enhancing microvascular stability (e.g., by providing platelet-
derived growth factor B for pericyte attraction), has been demonstrated to increase blood flow 
into ischemic myocardium, when added to VEGF-A (15). One vascular growth factor, which 
provides both capillary sprouting and pericyte investment, is Thymosin β4 (Tβ4) (16), which 
induces lasting and functional microvascular networks in wild-type (wt) animals, and stabilizes 
microvessels in the instance of inflammation (17). 
To determine whether microvascular destabilization affects organ function and 
therapeutic neovascularization in a clinically relevant large animal model, we studied ischemic 
cardiomyopathy in INSC94Y transgenic pigs, a model of permanent neonatal DM (18). In this 
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model, fasting glucose levels increased to 300 to 400 mg/dl after birth. We analyzed hearts of 5-
month-old diabetic (db) and wt pig hearts with or without hibernating myocardium, and applied 
regional adeno-associated virus (AAV)-based vascular gene therapy in the latter. Our results 
indicated that molecular treatment aiming at balanced vascular growth and maturation can 
improve hibernating myocardium in individuals with DM, although to a lesser extent than in age-
matched non-DM controls. 
METHODS 
Tissue samples of the nonischemic and ischemic animals (ramus circumflex [RCx] perfused 
area, wt and db) and patient samples (5 in the non-DM and 4 in the DM group, left ventricle 
[LV], ischemic area) were analyzed for capillary density (platelet endothelial cell adhesion 
molecule [PECAM]-1 positive cells) and pericyte investment (NG2 positive cells). More 
information about tissue staining is in the Online Appendix.  
Myocardial tissue specimens were procured from patients undergoing heart 
transplantation (Online Table 1). Patients provided informed consent for the scientific use of the 
explanted tissue. The study was approved by the institutional ethics boards of the clinical and 
experimental study contributors (H.M., A.D.). Specimens of LV myocardium (4 in the non-DM 
and 5 in the DM group) were obtained as 2 x 2 cm2 transmural biopsies from explanted failing 
hearts at the Heart and Diabetes Center of Northrhine Westphalia, and were prepared as 
described in the Online Appendix.  
Isometric contraction force was measured at a preload of 1 mN under continuous field 
stimulation (rate 0.5 Hz, pulse duration 3 ms) at 1.5-fold excitation threshold. Strain- and rate-
related alterations of contractility were determined in the presence of 1 µM isoprenaline. 
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Maximum twitch force was assessed at optimum preload. Tissue elastance was calculated from 
the increase in diastolic tension provoked by a 1 mm extension beyond relaxed length. 
The preparation of cells for direct matrigel assays, pericyte coculture experiments, and 
shear stress experiments is described in the Online Appendix. 
Recombinant AAV (rAAV)2.9 vectors encoding ß-galactosidase lacZ, Tβ4, or VEGF-A 
were produced using the triple transfection method as described earlier (19) and in the Online 
Appendix.  
Transgenic pigs presenting with permanent neonatal DM were generated as described 
previously (18). The INSC94Y mutation disrupts 1 of the 2 disulfide bonds between the A and B 
chains of the insulin molecule, resulting in misfolded insulin, impaired insulin secretion, 
endoplasmic reticulum stress, and apoptosis of the pancreatic beta cells. Consequently, these 
transgenic pigs present with permanent neonatal DM, which was treated with insulin until 7 days 
before experiment onset. Healthy nontransgenic littermates served as controls (Online Figure 
1A). 
German landrace pigs were anesthetized and instrumented as previously described (20) 
and in the Online Appendix. Of 37 animals initiated by stent placement, 5 (3 wt and 2 db) were 
lost due to sudden cardiac death during the first 28 days, whereas no animal was lost between 
days 28 and 56. The remaining 32 animals (14 wt, 18 db) were treated by mock transduction (5 x 
1012 rAAV containing no transgene; n = 7 wt, n = 6 db), rAAV.VEGF-A transduction (5 x 1012 
particles; n = 5 db), or rAAV.Tβ4 tranduction (5 x 1012 particles; n = 7 wt and db) via continuous 
pressure-regulated retroinfusion into the lateral vein (21). 
Twenty-eight days after implantation of a reduction stent, the myocardium was 
transduced with Tβ4 or VEGF-A by selective pressure regulated retroinfusion of 5 x 1012 
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rAAV.Tβ4 or 1x1013 rAAV.VEGF-A particles into the lateral vein, which anatomically drains 
the RCx-perfused myocardium (15) (Online Figure 1B). Four weeks later (day 56), we assessed 
collateral morphology and myocardial function as well as performed tissue harvesting for 
histochemical analysis. 
Global myocardial function was assessed at days 28 and 56 by means of a pressure-tip 
catheter placed in the left ventricle (for LV end-diastolic and systolic pressures, dP/dtmax, and 
dP/dtmin), whereas LV angiography was performed in anterior-posterior position for the analysis 
of ejection fraction (EF), yielding slightly smaller control values than a right anterior oblique 
view. At day 56, subendocardial segment shortening (SES) was performed after placing 
sonomicrometry crystal pairs into the ischemic (Cx-perfused) region and normalized to 
measurements in the control region (left anterior descending artery perfused area). Though 1 
animal of the treatment group died during SES assessment, it provided all other data.  
Post-mortem angiograms were taken for visualization of collateral formation and Rentrop 
score analysis: 0 = no filling; 1= side branch filling; 2 = partial main vessel filling; and 3 = 
complete main vessel filling. Tissue from nonischemic and ischemic LV myocardium was 
utilized for determining capillary density. 
STATISTICAL METHODS. The results are given as mean ± SE of the mean (SEM). 
Statistical analysis of results between more than 2 experimental groups was performed with 1-
way analysis of variance (ANOVA) in Figures 1B, 2B, 2C, 4B, and 4C; 2-way ANOVA was 
applied in all other figures that compared more than 2 groups and more than 1 condition. 
Whenever a significant effect was obtained with ANOVA, we performed multiple comparison 
tests between the groups using the Student Newman-Keule procedure. Two experimental groups 
were compared by Student t test. All procedures were performed with an SPSS Version 19.0.2 
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(IBM Corporation, Armonk, New York). Differences between groups were considered 
significant at p < 0.05. 
RESULTS 
Although diabetic microvascular alterations are well-known in peripheral or retinal tissue of 
patients, data are scarce that describe a structure-function correlation in diabetic hearts. 
Therefore, we first compared myocardium of end-stage hearts from patients with and without 
DM undergoing heart transplantation, utilizing specimens of freshly explanted hearts for 
histological and functional analyses. We found a distinct capillary rarefaction and pericyte loss in 
hearts derived from patients with DM (Figures 1A through 1C), accompanied by a lowered 
angiopoietin (Ang)1/Ang2 ratio in the DM group (Figure 1D). This microvascular alteration 
coincided with a loss of contractility in the papillary muscle ex vivo (Figure 1E). Moreover, 
wall stiffness, a parameter for impaired ventricular filling indicating diastolic heart failure, was 
found increased in the same hearts (Figure 1F), all confirming a correlation between 
microvascular disturbance and dysfunction in hearts from DM patients. 
Next, we investigated the impact of increased glucose levels on sprouting and maturation 
of endothelial cells in vitro. We used 2 well-known pro-angiogenic stimuli, VEGF-A and Tβ4 
(16), to induce tube formation of microvascular endothelial cells (bEnd3 and human umbilical 
venous endothelial cells). Under normal glucose conditions, cells displayed a high spontaneous 
tube formation rate, which was almost 2-fold increased upon Tβ4 stimulation (Figure 2A). Tube 
formation was reduced at high glucose concentration (61% of cells at normal glucose), but 
increased to 174% upon Tβ4 and 162% upon VEGF-A stimulation (Figure 2A). Consistently, 
Tβ4 enhanced the migratory capacity of endothelial cells in vitro in both normo- and high-
glucose conditions, although to a lesser extent in the high-glucose culture condition (Figure 2B). 
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Of note, while Tβ4 increased pericyte recruitment to the newly formed capillary rings at normal 
and high-glucose conditions, adding VEGF-A did not alter pericyte recruitment and high-glucose 
conditions impaired the capability of endothelial cells to attract pericytic cells to newly formed 
capillary rings (Figures 2C and 2D). 
The proangiogenic endothelial activation of Tβ4 under normal and high-glucose 
conditions did not induce pro-inflammatory events, since adhesion of monocytic THP-1 cells to 
endothelial cells decreased in both conditions upon Tβ4 treatment (Figure 2E). Nevertheless, 
adhesion of THP-1 cells on endothelial cells was found increased at high compared to normal 
glucose levels, pointing to a chronic inflammatory state of diabetic endothelium (Figure 2E). 
Next, we investigated the impact of high glucose levels on the microcirculatory status and 
myocardial function in otherwise unchallenged hearts in vivo. Noteworthy, at 5 months of age 
with blood glucose levels >300mg/dl (Figure 3A), a distinct capillary rarefaction was detectable 
in normoxic db pig hearts (163 ± 14 vs. 234 ± 8 capillaries/high power field [c/hpf] in wt) 
(Figures 3B and 3C). Moreover, pericyte investment of the remaining capillaries was decreased, 
rendering the microcirculatory networks in nonischemic hearts impaired (144 ± 6 vs. 219 ± 4 
pericytes [p]/hpf) (Figures 3B and 3D). Coincidentally, an increase in interstitial fibrosis was 
noted in db hearts (15.6 ± 0.6% vs.2.1 ± 0.5%) (Figures 3E and 3F). This structural alteration 
was associated with an impairment of systolic parameters such as EF (44.9 ± 1.9 % in db vs. 53.4 
± 1.2 in wt hearts) (Figure 3G). Consistently, db hearts demonstrated a decrease in functional 
reserve (6.6 ± 1.3% vs. 15.4 ± 2.3% at 150 beats/min) (Figure 3H) as well as an increase of LV 
end-diastolic pressure (12.7 ± 1.0 mm Hg vs. 8.2 ± 0.7 mm Hg) (Figure 3I). 
In a second set of experiments, we analyzed the response of diabetic porcine hearts 
(blood glucose >300 mg/dl) (Figure 4A) and age-matched control hearts subjected to regional 
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chronic ischemia inflicted by gradual occlusion of the circumflex artery. We found a higher 
degree of microcirculatory rarefaction in diabetic than in normoglycemic hibernating 
myocardium (129 ± 7 vs. 150 ± 4 c/hpf) (Figures 4B and 4C). Pericyte investment of capillaries 
was also decreased in diabetic hearts (106 ± 4 p/hpf vs. 136 ± 5 p/hpf) (Figures 4B through 
4D). Of note, rAAV.Tβ4 transduction significantly induced capillary growth and maturation in 
diabetic pigs (183 ± 9 c/hpf, 163 ± 14 p/hpf), although less pronounced than in wt hearts (294 ± 
6 capillaries/hpf, 286 ± 7 p/hpf; Figures 4B through D). Treatment of diabetic hearts with 
rAAV.VEGF-A treatment yielded an increase in capillaries (192 ± 4 c/hpf) Figures 4B and 4C). 
However, the pericyte investment did not concomitantly increase (87 ± 4 p/hpf) (Figures 4B and 
4D). 
The number of collaterals, which may be formed to compensate for chronic total RCx 
occlusion, was low in both db and wt groups (2.1 ± 0.5 vs. 1.9 ± 0.2 visible collaterals per heart) 
(Figures 4E and 4F). Upon rAAV.Tβ4 transduction, however, collateral formation increased to 
a larger extent in wt hearts (6.7 ± 0.5 collaterals/heart) than in diabetic hearts (4.7 ± 0.3 
collaterals/heart) (Figures 4E and 4F). Consistently, Rentrop score indicating distal filling of the 
occluded vessel reached a higher level wt hearts than in db hearts (2.6 ± 0.2 vs. 2.1 ± 0.1) 
(Figures 4E and 4G). Notably, rAAV.VEGF-A treatment did not increase arteriogenesis in the 
ischemic region of diabetic hearts (2.2 collaterals/heart,), with a Rentrop score at control level 
(rAAV.VEGF-A 1.2 ± 0.2 vs. control 1.4 ± 0.2) (Figures 4E through 4G) 
The structural impairment of diabetic microvasculature blunted the functional response of 
therapeutic neovascularization: the gain of EF induced by rAAV.Tβ4 treatment was less 
pronounced in the db compared to the wt group (Figures 5A and 5B, Online Figure 2A). 
Consistently, the rise in LV end-diastolic pressure observed in untreated ischemic animals 
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(Figure 5C, Online Figure 2B) was reversed after rAAV.Tβ4 treatment in either background 
(Figures 5C and 5D). Moreover, the level of regional myocardial function in the nonischemic 
area under rapid pacing was significantly reduced in diabetic hearts (db 8.8 ± 1.2 % vs. wt 16.7 ± 
1.0%) (Figure 5E). In the ischemic region, recovery upon rAAV.Tβ4 treatment was present in 
db hearts (8.5 ± 1.4% vs. 1.9 ± 0.8% in untreated db hearts), but significantly less pronounced 
than in wt hearts (rAAV.Tβ4 16.0 ± 1.2%) (Figure 5F). In the ischemic region of db hearts, 
rAAV.VEGF-A did not alter functional reserve (2.9 ± 0.7%) (Online Figure 2C). 
Since the complex myovascular interaction in diabetic hearts destabilized microvessels 
and inhibited therapeutic vessel growth, we investigated the Ang1/Ang2 ratio in the ischemic 
hearts. The reduced Ang1/Ang2 ratio in ischemic tissue was enhanced upon Tβ4 overexpression 
in wt as well as db hearts (Figure 6A, Online Figure 1C). However, rAAV.VEGF-A application 
did not improve the Ang1/Ang2 ratio, pointing to the lack of mature microvascular growth. In 
addition, we investigated the alterations in micro ribonucleic acid (miR), which might account 
for the pleiotropic actions induced by the hyperglycemic state. Three vasoactive miRs were 
found upregulated in the hyperglycemic hearts (Online Figure 3): miR 26a, which is implicated 
in impaired wound healing angiogenesis in DM (22); miR92a, a known inhibitor of cardiac 
angiogenesis (23,24); and miR133a, whose level was previously reported to be elevated in 
diabetic hearts (25). We found these 3 miRs significantly upregulated in the porcine diabetic 
hearts (Online Figure 3), suggesting them as potential novel mediators of microvascular 
rarefaction in DM. Furthermore, fibrosis was induced in the ischemic tissue (db 22.5 ± 1.0% vs. 
wt 19.0 ± 0.8%) (Figures 6B and 6C). rAAV.Tβ4 application significantly reduced fibrosis in 
db as well as wt hearts (13.1 ± 0.6 % and 11.0 ± 0.4%, respectively) (Figure 6B and 6C). 
DISCUSSION 
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In the current study, we assessed the impact of cardiovascular risk factors on the induction of 
vascular growth in the micro- and macrovascular compartment. We found that diabetic human 
hearts displayed capillary rarefaction and pericyte loss, accompanied by decreased contractility 
and increased stiffness (Figure 1). Moreover, hyperglycemia attenuated tube formation, 
migration, and pericyte attraction upon proangiogenic stimulation in vitro (Figure 2). In vivo, 
untreated DM induced microcirculatory rarefaction (Figure 3) and a distinct functional cardiac 
impairment in a transgenic INSC94Y pig model. Induction of regional chronic ischemia impaired 
microvascular density in both hyper- and normoglycemic hearts, without functional 
collateralization of the ischemic region (Figure 4). Forced angiogenesis via rAAV.VEGF-A, 
without concomitant vessel maturation, had no significant effect on regional and global function 
at rest and under rapid pacing (Figures 4 and 5). However, balanced vascular growth was 
induced via rAAV.Tβ4 in db pig hearts, though to a significantly lesser extent than in wt hearts 
(Figure 4). Functional impairment of hibernating myocardium was improved in db hearts upon 
Tβ4 treatment, albeit not to the same extent as in normoglycemic hearts (Figure 5). MiR analysis 
of db hearts revealed increased concentrations of antiangiogenic miR 26a, 92a, and 133a. 
Additionally, a higher degree of fibrosis was observed, which was partially reversed by Tβ4 and 
VEGF-A (Figure 6, Online Figure 3). The Central Illustration depicts the specific 
microcirculatory alterations of DM and the effects of Tβ4 and VEGF-A. 
Notably, uncontrolled diabetes with continuously elevated glucose levels (Figure 3A) 
itself suffices to rarefy microcirculatory density of cardiac muscle. Capillary loss and pericyte 
dropout have been well described in the retina (26), but are revealed for the first time in 
transgenic db pig hearts and in hearts from patients with diabetes. Previously, microvessel 
destabilization has been attributed to Ang2 overexpression (27). A partial inhibitor of the Tie2 
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receptor, Ang2 might destabilize microvessels by antagonizing the Ang1/Tie2 interaction, which 
provides a quiescent and mature vessel state. This feature has been attributed to inflammatory 
destabilization of microvessels in sepsis (28), but may also occur in chronic inflammatory 
endothelial activation (26) or in streptozotocin-induced experimental DM (29). Notably, 
increased Ang2 expression has been found in aged db/db mice characterized by capillary 
rarefaction and fibrosis (30). In our study, the ratio of Ang1/Ang2 was slightly, but not 
significantly, decreased in db pig and human hearts compared to normoglycemic hearts (Figures 
1D and 6A, Online Figure 1C), but increased upon rAAV.Tβ4 treatment. In the human tissue, 
Tβ4 expression was unaltered even though DM human corneas display a distinct Tβ4 reduction 
(31). However, the vascular growth induction by Tβ4 was previously found to be sensitive to 
Ang2 (16). Thus, an improved Ang1/Ang2 ratio appears crucial for the balanced vascular growth 
provided by rAAV.Tβ4. 
Interestingly, rAAV.VEGF-A had no effect on the Ang1/Ang2 ratio (Figure 6A, Online 
Figure 1C). This was consistent with our previous observation in normoglycemic chronic 
ischemic pig hearts (15), where rAAV.VEGF-A did not yield sufficient microvessel maturation 
nor macrovessel growth (arteriogenesis) for functional improvement in our hibernating 
myocardium model. Lack of microvessel maturation was found critical, since addition of 
placenta-derived growth factor B to VEGF-A sufficed to induce augmentation of micro- and 
macro-vessels as well as functional improvement (15). 
With rAAV.Tβ4 treatment, we found a decrease of CD14+ monocytes, representing the 
proinflammatory M1 phenotype, in normo- as well as hyperglycemic pig hearts (Online Figure 
1D). One potential signal triggering continuous inflammation is increased binding of advanced 
glycation endproducts to their receptor (RAGE) (14). Besides its intracellular pro-inflammatory 
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signaling and high mobility group box 1- and nuclear facto κB-dependent upregulation of 
adhesion molecules (32), cytokines, and chemokines, RAGE itself interacts with Mac-1 on 
circulating leukocytes, mediating firm adhesion (33,34) and further inflammatory stimulation. 
Moreover, in metabolic stress (like DM) endosomal damage-associated molecular patterns may 
activate the inflammasome for a perpetual inflammatory state (35). Finally, miR alterations may 
take a toll of microvascular preservation. In this respect, miR 92a, miR 26a, and miR133b have 
shown a distinct increase in hyperglycemia (Online Figure 3), which may indicate their 
involvement in diabetic vascular rarefaction and suggest them as potential therapeutic targets for 
miR inhibitors (24). 
STUDY LIMITATIONS. In this study, we used a transgenic pig model of insulin-dependent 
DM to investigate the efficacy of vascular gene therapy using rAAV.Tβ4 and rAAV.VEGF-A as 
therapeutic agents. Thus, we analyzed an untreated cardiac risk factor, representing a ‘worst 
case’ scenario for a potential loss of treatment function. We assume that most patients of the 
target population receive current medical treatment schemes, blunting the described loss of 
efficacy. Nevertheless, comorbidities like DM must be taken into account when calculating the 
size of a potential treatment effect. 
CONCLUSIONS 
We used a transgenic diabetic pig model to quantify vessel growth and functional improvement 
in hibernating myocardium subjected to rAAV.Tβ4 therapy to improve neovascularization. Our 
results indicated an attenuated, but still significant, increase of micro- and macro-vessels that 
improved myocardial function. Thus, we concluded that in the presence of diabetes mellitus, 
balanced vascular gene therapy, targeting microvascular maturation and macrovascular growth in 
14 





Competency in Medical Knowledge:  In a transgenic, porcine model of diabetes mellitus 
(InsC94Y), microcirculatory instability compromises myocardial function and angiogenesis. 
Translational Outlook:  Future research should seek ways to promote capillary stability in 
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FIGURE LEGENDS 
CENTRAL ILLUSTRATION Tβ4 Gene Therapy and Therapeutic Neovascularization   
Diabetes mellitus impairs vascular density in the heart. Proangiogenic gene therapy via 
Thymosin β4 (Tβ4) or vascular endothelial growth factor-A (VEGF-A) induces capillary growth 
in diabetic heart. However, only Tβ4 is capable of inducing therapeutic neovascularization via 
vessel growth and maturation, thereby improving perfusion and myocardial function in ischemic 
normal as well as diabetic hearts.  
FIGURE 1 DM Alters Cardiac Function   
(A) Tissue samples of patients with diabetes mellitus (DM) undergoing heart transplantation 
display capillary rarefaction. (B) Besides a reduced capillary density (PECAM-1+), (C) these 
patients demonstrated a loss of pericytes (NG2+). (D) DM status did not change expression of 
Thymosin β4 (Tβ4) in the human cardiac tissue of end-stage heart failure patients. The ratio of 
angiopoietin (Ang) 1 and 2 expression was reduced patients with DM. (E) Force development of 
human cardiac tissue slides revealed a reduced contractile function in DM patients undergoing 
heart transplantation. (F) Ventricular stiffness is impaired in DM heart slices compared to non-
DM samples. Mean ± SEM; n = 4; *p < 0.05. hpf = high power field; PECAM-1 = platelet 
endothelial cell adhesion molecule-1. 
FIGURE 2 High Glucose Levels Alter Proangiogenic Effects   
(A) Tube formation capacity of murine endothelial cells is altered under high-glucose levels; Tβ4 
and vascular endothelial growth factor-A (VEGF-A) transfection enhanced tube formation under 
normo- and high-glucose levels (scale bar = 200 µm). (B) Similarly, high glucose reduced 
endothelial cell migration in vitro in a wound-scratch assay (red area = uncovered area; scale bar 
= 200 µm) while Tβ4 or VEGF-A overexpression enhanced migration capacity in normo- and 
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high-glucose conditions. (C and D) High-glucose levels reduced tube maturation, assessed as 
pericyte recruitment (green fluorescence) to endothelial rings (red fluorescence; scale bar = 100 
µm); transfection of Tβ4, but not VEGF-A, enhanced maturation at normo- and high-glucose 
levels. (E) High-glucose levels increased adhesion of human monocytic THP-1 cells under 
venular shear stress (4 dyn/s; scale bar = 100 µm); Tβ4 transfection reduced this endothelium-
leukocyte interaction in normo- and high-glucose levels. Mean ± SEM; n = 3. *p < 0.05; **p < 
0.001. Abbreviations as in Figure 1. 
FIGURE 3 Capillary Rarefaction  
(A) Fasted blood glucose levels are enhanced in the transgenic diabetic (db) pigs (C94Y 
mutation in the porcine insulin gene) compared to the wild-type (wt) littermates. In cardiac 
tissue, (B and C) capillary density (PECAM-1+) as well as (B and D) vessel integrity (NG2+) 
were reduced in the transgenic db versus wt pigs. (E and F) Fibrosis (scale bar = 100 µm) was 
significantly increased in db hearts. Transgenic db pig also demonstrated (G) reduced ejection 
fraction (EF) and (H) diminished contractile functional reserve assessed by subendothelial 
sonomicrometry at rest and rapid atrial pacing (120 and 150 beats/min). (I) Left ventricular end-
diastolic pressure (LVEDP) increased under high-glucose conditions in db pigs. Mean ± SEM; n 
= 4. *p < 0.05; **p < 0.001. SES = subendocardial segment shortening; other abbreviations as in 
Figures 1 and 2. 
FIGURE 4 DM Relevance for Vascularization in Chronic Myocardial Ischemia  
(A) Fasted blood glucose levels are enhanced in db pigs at days 0, 28, and 56 versus their age-
matched wt littermates. Chronic myocardial ischemia leads to (B and C) capillary rarefaction 
(PECAM-1+) in both wt and db pig hearts. The reduced capillary number is associated with (B 
and D) a loss of pericytes (NG2+) in the ischemic tissue in both control groups. This effect was 
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at least partially reversed after rAAV.Tβ4 transduction, less so in db animals, an effect not 
observed after rAAV.VEGF-A application. (E) Representative pictures and (F) quantification of 
collateral growth, measured at day 56, which was enhanced after rAAV.Tβ4 application; 
rAAV.VEGF-A application showed no cardioprotective effect. (G) Perfusion of the vessel distal 
to the occlusion site, displayed as Rentrop score, revealed a reduced filling in wt and db control 
animals. Tβ4, but VEGF-A overexpression, was capable of enhancing vessel perfusion. Mean ± 
SEM; n = 6 to 8. *p < 0.05; **p < 0.001. rAAV = recombinant adeno-associated virus; other 
abbreviations as in Figures 1, 2, and 3. 
FIGURE 5 Tβ4-induced Cardioprotection  
(A) Systolic myocardial function, measured by EF, improved in rAAV.Tβ4-transduced but not 
rAAV.VEGF-A treated animals at day 56.  (B) Change from day 28 to 56 (ΔEF) showed 
comparable changes in wt and db rAAV.Tβ4 animals, although at different levels. (C) LVEDP 
increased in wt and db ischemic hearts day 28 to 56, unless Tβ4 was overexpressed. VEGF-A 
transduction did not reduce the enhanced LVEDP in the ischemic db hearts. (D) Change from 
day 28 to 56 (ΔLVEDP) showed similar effects in wt and db rAAV.Tβ4 animals, but at different 
levels. (E) Functional reserve in the nonischemic (left anterior descending region) tissue is 
diminished in db hearts compared to normo-glycemic animals. (G) In the ischemic (ramus 
circumflexus region), rAAV.Tβ4 application enhanced myocardial contractile function in both 
wt and db animals, while rAAV.VEGF-A showed no protective effect. Mean ± SEM; n = 6 to 8. 
*p < 0.05; ** p < 0.001. Abbreviations as in Figures 1, 2, 3, and 4. 
FIGURE 6 DM-induced Molecular Alterations   
(A) Ang1/Ang2 expression improved after Tβ4 but not VEGF-A transduction in both wt and db 
animals. (B and C) Chronic myocardial ischemia-induced fibrosis (scale bar = 100 µm) is 
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accelerated under diabetic conditions (wt control vs. db control). Overexpression of Tβ4 or 
VEGF-A significantly reduced fibrosis in the ischemic tissue in both wt and db hearts. Mean ± 









Online Figure 1: A Protocol of the hibernating myocardium model in diabetic and wild-type 
pigs. B RT-PCR detection of virus transduction in heart tissue of control (wt) and diabetic 
transgenic (db) pigs (ΔΔCT values normalized to control animals). C Expression profile of 
Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) showed an increase of Ang-2 expression in 
the db compared to wt animals, an effect sensitive to Thymosin β4 but not VEGF-A 
transduction. D Analysis of inflammation in the ischemic tissue (CD14 positive cells/low power 
field), showing a decrease of inflammation after Tß4 overexpression in wt as well as db animals. 
This effect was not observed after VEGF-A transduction in the db hearts. (Mean ± SEM, n=4, * 
p<0.05, ** p<0.001) 
Online Figure 2: A Left ventricular end-diastolic pressure (LVEDP) increased in ischemic wt as 
well as db hearts from day 28 to 56, unless Thymosin β4 was overexpressed. VEGF transduction 
did not reduce the enhanced LVEDP in the ischemic db hearts. B Analysis of ejection fraction 
revealed an improvement of systolic myocardial function after rAAV.Tβ4 treatment of wt and db 
animals at day 56. No gain of ejection fraction was found in rAAV.VEGF-A treated hearts. C 
Regional myocardial function is assessed by subendocardial segment shortening at rest and under 
atrial pacing (120 and 150 bpm). The functional reserve in the ischemic area in relation to the 
non-ischemic (LAD region) tissue is enhanced after rAAV.Tβ4 application to the same extent in 
wt and db animals, VEGF-A however, showed no protective effect (Mean ± SEM, n=6-8, * 
p<0.05, ** p<0.001). 
Online  Figure 3: miRNA expression analysis in wt and db non-ischemic heart tissue displayed 
a significant up-regulation of miRNA-26a, miRNA-92a and miR-199a in diabetes. 
  
Online Table 1 
 non-diabetic diabetic 
Group size (n) n=5 n=4 
Age (years) 54±3 60±4 
Gender (m/f) 3/2 4/0 
Co-morbidities   
ICM 3 2 
DCM 2 2 





From Methods Section 
(page numbers from v3) 
 
Page 4 
Capillaries were stained with a CD31 (PECAM)-antibody, whereas vessel maturation was 
quantified by pericyte (NG2 antibody) costaining. Pictures were taken with high-power field 
magnification (40-fold) and 5 independent pictures per region and animal were quantified. 
Fibrosis staining was performed by Sirius red oil staining in nonischemic and ischemic 
animals (wt and db). Pictures were taken at a 10-fold magnification (low power field). Red 
fibrotic area in percent was quantified via ImageJ v.1.43u in 5 independent pictures per region. 
Pro-inflammatory cells (macrophages) were stained with a CD14 antibody in the 
ischemic tissue. Pictures again were taken with low power field magnification (10-fold) and 5 




Specimens of LV myocardium (4 in the non-DM and 5 in the DM group) were obtained 
as 2 x 2 cm2 transmural biopsies from explanted failing hearts at the Heart and Diabetes Center 
of Northrhine Westphalia, and were immediately placed in cold (4° C) HEPES buffered salt 
solution containing 30 mM BDM (3-butanedione 2-monoxime). Samples were sent by overnight 
courier to the Walter-Brendel-Center, Munich, where 300 µm thick tissue slices were prepared 
within 18 to 31 h after surgery, as previously described (19). Briefly, trimmed tissue blocks were 
embedded in 4% agarose, mounted onto a vibratome, and cut along the transversal direction 
proceeding from the endocardial to epicardial layers of the myocardium. 
Freshly prepared myocardial slices of 5 x 5 mm2 surface area were mounted onto a horizontal 
organ bath, and superfused with gassed Ringer solution (5 % CO2, 20 % O2, 37° C) at 4 ml/min 
as previously described (19).  
 
Pages 5-6 
For direct matrigel assays, human umbilical vein endothelial cells (HUVEC) were 
transfected with pcDNA, Tβ4, or VEGF-A. Cells were diluted to a final density of 10,000 
cells/50 µl and seeded on matrigel. Pictures were taken after 18 h. Number of rings per low 
power field was quantified. 
For pericyte co-culture experiments murine endothelial cells (bEnd.3) were transfected 
with pcDNA, Tβ4, or VEGF-A as described previously. Endothelial cells were stained with DiD 
(red, Vybrand), diluted to a final density of 10,000 cells/30µl and seeded on matrigel. After 18 h, 
tube formation was investigated. Murine embryonic pericytes were cultured according the 
manufacturer´s instructions and added to the pre-formed tubes (1,000 cells/15µl per well, pre-
labeled green, DiO, Vybrand). After 6 h of coculture, pictures were taken by confocal laser 
microscopy and the PC per tube ratio was analyzed. 
For detection of leukocyte adhesion shear stress experiments were performed as follows: Ibidi-
slides were seeded with HUVEC which were under normo- or high-glucose and transfected with 
pcDNA or Tβ4. After 24 h, when the cell layer was confluent, THP-1 cells (leukocyte cell line) 
were superfused at a density of 750,000 cells per ml and at a flow rate of 0.57 ml/min (1 
dyn/cm²). After 8 min of cell superfusion and 2 min of washing with medium only (at the same 
flow rate), adherent cells were counted. 
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Briefly, transfection of HEK293 cells was performed using 1 plasmid encoding the 
transgene under control of the CMV promoter flanked by cis acting AAV2 internal terminal 
repeats, a second plasmid providing AAV2 rep and AAV9 cap in trans, whereas a third plasmid 
supplemented adenoviral helper function using polyethylenimine. Titers of the rAAVs were 
determined via quantitative real time polymerase chain reaction (qRT-PCR) against the bGH 




Briefly, ischemia was induced by emplacing a reduction stent (2.5 x 13mm, Jomed, Germany) 
(22) into the proximal RCx, inducing a 75% stenosis which progressed to total occlusion at day 
28 (Online Figure 1A). This model is characterized by hibernating myocardium (dysfunctional, 
but viable and metabolically hyperactive, cf. [22]), functionally responding to improvement of 
microcirculatory blood flow, as assessed by fluorescent microspheres (16,23). A marker of 
gradual stent occlusion and an inclusion criterion was an area of infarcted myocardium <6% of 
total LV area at d56 (tetrazolium-red-staining). 
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